

Tyrian Diagnostics Limited ACN 080 277 998

TYRIAN SHIPS FIRST COMMERCIAL ORDER TO BAYER FROM OUTSOURCED MANUFACTURER

SYDNEY, AUSTRALIA 23 September 2010: Tyrian Diagnostics Limited (ASX:TDX) is pleased to announce today that it has successfully fulfilled a commercial order of ReadRite™ Alpha-Amylase diagnostic tests for Bayer CropScience AG, with product manufactured on site by its outsourced manufacturer, Pacific Biotech Co. Ltd in Thailand.

The majority of these ReadRite Alpha Amylase test kits will be sold to a key industry body in Canada, a major wheat producing country, for extended field evaluation studies. This season's wet harvest conditions in Canada could lead to a high level of pre-harvest sprouting of the grain creating strong interest for testing.

The balance of the test kits will be used for the completion of a product validation study by the primary government agency in the US. The extensive trials being undertaken by these key industry and government bodies in Canada and the US are critical for widespread adoption of the ReadRite products in these countries.

Dr Jenny Harry, CEO of Tyrian, commented "The completion of this commercial batch of the ReadRite products is an important milestone, as it demonstrates that we have successfully achieved the transfer of technology to our contract manufacturer. We now have a platform for the commercial high volume manufacture of current and future DiagnostIQ test products. I am also very pleased with the attention being paid to the ReadRite test by the key industry and government bodies in the Canada and US, given the importance of their endorsement for commercial success of the products."

About DiagnostIQ™

DiagnostIQ™ is a patented diagnostic test platform suitable for the development of antibody-based, Point-of-Need diagnostic tests. The platform is simple to use, rapid, robust, sensitive and suitable for analyzing complex samples. A combination of features provides a versatile platform for use with a variety of sample types and products for medical, veterinary and agriculture applications. The DiagnostIQ test can provide a visual result and/or be used with a portable digital reader when quantitative test results are required. Bayer CropScience AG has obtained the exclusive worldwide license for two application areas of the DiagnostIQ platform.

About Tyrian Diagnostics

Tyrian Diagnostics (ASX: TDX) is an Australian-based company that develops and commercialises rapid point-of-need diagnostics.

The Company has an innovative and proprietary diagnostic test platform, DiagnostIQ, and Tyrian's strategy is to deliver near term revenues through partnering this technology for the development and commercialisation of clinical and non-clinical diagnostic tests. The first product is a point-of-need diagnostic for measuring wheat quality, ReadRite Alpha Amylase, developed in partnership with Bayer CropScience AG, with further products under development.

Tyrian also has expertise in discovering and developing biomarkers of disease as targets for diagnostic tests. Tyrian's primary internal programme is the development of its patented biomarkers for molecular and protein-based diagnostic tests for active tuberculosis (TB) and the company is seeking partners for final development and marketing of these tests. Tyrian's longer term plan is to exploit its intellectual property and expertise in respiratory and infectious diseases to achieve higher returns through developing and commercialising proprietary clinical diagnostic products.

Additional information about Tyrian Diagnostics can be found at www.tyriandx.com

Contact:

Tyrian Diagnostics
Dr Jenny Harry
Chief Executive Officer
+61 2 8877 8947